The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 05, 2024
Filed:
Apr. 25, 2018
Applicants:
Istituto Europeo Di Oncologia S.r.l., Milan, IT;
Università Degli Studi Di Milano, Milan, IT;
Inventors:
Assignees:
Istituto Europeo di Oncologia S.r.l., Milan, IT;
Università degli Studi Di Milano, Milan, IT;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 31/135 (2006.01); A61K 31/165 (2006.01); A61K 31/167 (2006.01); A61K 31/18 (2006.01); A61K 31/325 (2006.01); A61K 31/343 (2006.01); A61K 31/366 (2006.01); A61K 31/4025 (2006.01); A61K 31/4045 (2006.01); A61K 31/407 (2006.01); A61K 31/4155 (2006.01); A61K 31/4184 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); A61K 31/4406 (2006.01); A61K 31/4439 (2006.01); A61K 31/445 (2006.01); A61K 31/47 (2006.01); A61K 31/473 (2006.01); A61K 31/495 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5375 (2006.01); A61K 31/549 (2006.01); A61K 38/15 (2006.01); A61P 35/02 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/135 (2013.01); A61K 31/165 (2013.01); A61K 31/167 (2013.01); A61K 31/18 (2013.01); A61K 31/325 (2013.01); A61K 31/343 (2013.01); A61K 31/366 (2013.01); A61K 31/4025 (2013.01); A61K 31/4045 (2013.01); A61K 31/407 (2013.01); A61K 31/4155 (2013.01); A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/4406 (2013.01); A61K 31/4439 (2013.01); A61K 31/445 (2013.01); A61K 31/47 (2013.01); A61K 31/473 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5375 (2013.01); A61K 38/15 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01);
Abstract
The present disclosure relates to methods of treating cancer and pharmaceutical compositions for use in the treatment of cancer, including LSD1-inhibitor-resistant cancers, comprising administering to a subject an effective amount of a cell cycle inhibitor, such as a CDK4/6 inhibitor or a p21 enhancer, and an effective amount of a LSD1 inhibitor.